Zhao et al. (24) performed a radiomic analysis of 87 brain metastases from 24 ALK-positive NSCLC patients treated with the ALK inhibitor ensatinib and established a model based on nine enhanced T1-weighted MRI radiological features that predicted the intracranial progression within 51 weeks (AUC = 0.85). Here, ALK is linked to non-small cell lung carcinoma.